Peptigrade

Metabolic & Weight

Lipo-C

Lipotropic injection (MIC) — methionine + inositol + choline, typically with cyanocobalamin (B12) and variable B-complex (B1/B2/B5/B6)·Also known as: MIC, MIC B12, MIC+, Lipo-Mino, Lipotropic injection, Lipo shot, Skinny shot

FDARegulatory status

Not an FDA-approved drug. Lipo-C is a compounded preparation — a specific combination of methionine, inositol, choline, and B-vitamins that has never been evaluated by FDA for the weight-loss indication it is marketed for. Individual components have varied regulatory standing: injectable methionine and choline do not have FDA-approved finished-drug NDAs for weight loss; cyanocobalamin injection is FDA-approved for B12 deficiency (NDA 080250 and others), not for weight loss. Lipotropic injections are produced by state-licensed 503A compounding pharmacies for individual patients on a prescription; 503B outsourcing facilities cannot produce them unless the components appear on FDA's 503B bulks list or are a component of an approved drug. FDA issued a consumer update (July 2023, reiterated in subsequent compounding alerts through 2025) warning against compounded injectable products marketed for weight loss, and the April 15, 2026 FDA 503A Categories Update continues to flag injectable weight-loss compounds as a compliance focus area. No Lipo-C / MIC product has a Drug Efficacy Study Implementation (DESI) review supporting the combination for fat loss.

WADARegulatory status

Not specifically listed as a named substance on the 2026 WADA Prohibited List (in force January 1, 2026). Individual components — methionine, inositol, choline, cyanocobalamin, and B-complex vitamins — are endogenous metabolites or essential nutrients and are not restricted. However, WADA's S0 (non-approved substances) clause can apply to any compounded preparation not approved for human therapeutic use by a governmental regulatory authority; athletes using compounded Lipo-C do so at their own risk and should clear it with their anti-doping authority.

Regulatory note ·Lipo-C is not a single molecule — it is a compounded mixture, and formulation varies materially between clinics. A representative 'MIC' formula is methionine 25 mg/mL + inositol 50 mg/mL + choline chloride 50 mg/mL; 'MIC+' or 'Lipo-Plus' formulas add cyanocobalamin 1,000 mcg/mL and variable thiamine (B1), riboflavin-5-phosphate (B2), dexpanthenol (B5), and pyridoxine (B6). The typical IM or SC dose is 1 mL once or twice weekly in medical weight-loss clinics. Because each compounded batch is a distinct preparation, safety, potency, sterility, and pH vary with the compounder. The FDA's compounding risk alerts specifically flag sterility, endotoxin load, and mislabeling in injectable weight-loss compounds as recurring inspection findings.

§ The quick take

TL;DR · Editor’s summary

Lipo-C is not a peptide and not a single drug — it is a compounded injectable mixture of methionine, inositol, and choline (the 'MIC' core), typically with cyanocobalamin and often a rotating B-complex, sold through medical weight-loss clinics at $20–$75 per shot for a once- or twice-weekly IM or SC injection. The grade is driven by one central fact: no randomized, placebo-controlled trial of the MIC combination as an injection for fat loss has been published in the peer-reviewed literature. Not a negative trial — no trial.

The 'lipotropic' framing descends from 1930s–1950s rodent work (Best 1932 on choline-deficiency fatty liver; Best 1951 on inositol's statistical effect on hepatic lipid in rats) showing that choline or methionine deficiency induces hepatic steatosis and that supplementation reverses it. Reversing an induced deficiency in a rat is not the same as causing net fat loss in a non-deficient human, and the literature reviewed by Corbin (2012) and Sherriff (2016) does not close that gap. The component-level evidence is real but narrow and does not sum to the marketed claim: oral inositol improves insulin sensitivity in PCOS at 2–4 g/day (Unfer 2017 meta-analysis) — a dose ~40–80× the weekly inositol in a typical Lipo-C shot, delivered by a different route, in a different population; B12 injection corrects fatigue in frank deficiency (Stabler 2013 NEJM) but not in replete adults; choline affects VLDL assembly in TPN-associated steatosis but not as a weight-loss agent.

The FDA's 2023 consumer update on compounded injectable weight-loss products, reiterated through the April 15, 2026 503A Categories Update, specifically flags sterility, endotoxin, and mislabeling risk from 503A compounders producing these mixtures. For a clinician: Lipo-C's weight-loss grade is D because the evidence pattern is 'zero RCTs of the mixture + plausible-but-unvalidated mechanistic story + marketing claims that run well ahead of the data' — the same pattern that earns a D across our rubric. Patients who report 'it works' are almost always in a caloric deficit, on a GLP-1, or experiencing a B12-deficiency correction; those three explanations together cover the observed clinical picture without needing the lipotropic claim to be true.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Lipo-C, sorted by strength of evidence.

Pend.

Weight loss / fat loss (the marketed indication)

Pending · Below evidence threshold

No randomized, placebo-controlled trial of the MIC combination as an injection for weight loss has been published in the peer-reviewed literature. Clinic-reported 'before-and-after' data is uncontrolled and typically confounded by concurrent caloric restriction, GLP-1 co-administration, and B12 energy-perception effects. The component-level evidence does not aggregate to an efficacy claim for the mixture.

0 studiesUpdated 2026-04-21
D

Hepatic steatosis / NAFLD (mechanism-adjacent)

Weak

Choline and methionine deficiency reliably induces fatty liver in rodents (the MCD-diet model, Rinella 2008) — this is the mechanistic origin of the 'lipotropic' label. Reversing an induced deficiency is not the same as a therapeutic effect in non-deficient humans. Corbin (2012, Curr Opin Gastroenterol) reviews the clinical data and finds no RCT of MIC injection for NAFLD; oral choline supplementation trials in TPN-associated steatosis are the strongest human signal.

3 studiesUpdated 2026-04-21
D

Energy / fatigue improvement (attributed to B12 component)

Weak

B12 injection corrects fatigue in frank B12 deficiency (Stabler 2013, NEJM). In non-deficient adults, controlled trials of B12 supplementation for fatigue are negative or equivocal. The 'energy boost' reported by Lipo-C patients is most parsimoniously explained by the B12 component acting on a minority of patients with subclinical deficiency, not by the lipotropic ingredients.

4 studiesUpdated 2026-04-21
Pend.

Lipid profile improvement (LDL, triglycerides)

Pending · Below evidence threshold

Oral choline and betaine can modestly affect plasma lipids in metabolic-syndrome cohorts (Olthof 2005). No trial of injected MIC has measured a controlled lipid-panel outcome. Any 'improvement' seen in weight-loss-clinic chart reviews is confounded by the concurrent hypocaloric diet.

2 studiesUpdated 2026-04-21
C

Insulin sensitivity (attributed to inositol component)

Mixed

Oral myo-inositol and D-chiro-inositol at 2–4 g/day improve insulin sensitivity in PCOS (Unfer 2017 meta-analysis of 9 RCTs). This is an oral, component-specific, PCOS-population finding — not evidence that 50 mg of inositol in a weekly IM injection produces the same effect. Generalizing the inositol-in-PCOS literature to the Lipo-C indication is a category error.

9 studiesUpdated 2026-04-21
Ins.

Body composition when added to GLP-1 therapy

Insufficient

Many medical weight-loss clinics stack Lipo-C with semaglutide or tirzepatide and attribute composite results to the mixture. No controlled study has isolated the Lipo-C contribution from the GLP-1 effect. The weight change is almost entirely attributable to the GLP-1, per the STEP (Wilding 2021) and SURMOUNT (Jastreboff 2022) trial effect sizes.

0 studiesUpdated 2026-04-21

§ Why this grade

Sub-scores for this outcome.

Weight loss / fat loss (the marketed indication)

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

2 / 5

Individual components have well-characterized biochemistry (methionine → SAM → PEMT; choline → Kennedy-pathway PC → VLDL; inositol → PIP₃ → insulin signaling; B12 → methionine synthase). What is not established is the mechanistic path from 'a 1 mL IM injection of this mixture' to 'net negative fat balance.' The mechanism argument works backward from a deficiency model (reversing MCD-diet NASH in rats) to a claim that does not fit the usual non-deficient human target population.

Human studies (count + quality)

1 / 5

Zero RCTs of MIC injection for weight loss. Component-level oral trials exist — inositol in PCOS (Unfer 2017, 9 RCTs), oral choline in TPN steatosis (Buchman 1995), B12 in deficiency — but these are the wrong substance, dose, route, and population to support the Lipo-C weight-loss claim.

Effect vs placebo

1 / 5

No placebo-controlled trial of MIC injection has been published. Clinic-reported outcomes come with concurrent hypocaloric diet, GLP-1 co-administration, and expectancy effect — exactly the confounders that placebo control is designed to isolate.

Long-term safety data

3 / 5

Component-level long-term safety is well-characterized: methionine, inositol, choline, and B12 are essential nutrients with decades of oral safety data. Long-term (>12 month) weekly IM injection of the mixture in non-deficient adults is less characterized. Repeated IM B-complex is generally well-tolerated but 503A-compounder sterility variance is a real failure mode flagged by FDA.

Side effect profile

3 / 5

Usually well-tolerated: injection-site pain, transient flushing, urine odor (methionine), dysgeusia (B-complex). Reported rare adverse events: sterile abscess, infectious abscess from compounded-product contamination, allergic reaction to cyanocobalamin or preservative, and transient paresthesia. The profile is benign enough that a patient who does not lose weight will also rarely be harmed — but 'safe' is not the same as 'effective.'

Regulatory status

1 / 5

No FDA-approved finished-drug product exists for the MIC combination. Lipo-C is a 503A-compounded preparation without a DESI efficacy review. FDA's 2023 consumer update on compounded injectable weight-loss products and the April 15, 2026 503A Categories Update flag the compound class for compliance attention. Not WADA-named but the S0 non-approved-substances clause can apply.

§ What the science says

How Lipo-C
works.

Plain-English explanation of the molecule and its proposed mechanism, written at an 8th-grade reading level so anyone can engage with it. Every claim is linked to a primary source below.

What it is

Lipo-C is a compounded aqueous injection typically produced by 503A pharmacies under USP <797> sterile-compounding rules. The MIC core is L-methionine (C₅H₁₁NO₂S, 149.21 Da, CAS 63-68-3), myo-inositol (C₆H₁₂O₆, 180.16 Da, CAS 87-89-8), and choline chloride (C₅H₁₄ClNO, 139.62 Da, CAS 67-48-1); the most common augmented formula ('MIC+' or 'MIC B12') adds cyanocobalamin (C₆₃H₈₈CoN₁₄O₁₄P, 1355.37 Da, CAS 68-19-9) and rotating B-complex vitamins (thiamine HCl, riboflavin-5'-phosphate, dexpanthenol, pyridoxine HCl). Representative concentrations are methionine 25 mg/mL, inositol 50 mg/mL, choline chloride 50 mg/mL, cyanocobalamin 1,000 mcg/mL — but formulation is not standardized across compounders and there is no USP monograph for 'Lipotropic Injection.' The solution is typically clear to light pink (the red color of cyanocobalamin's cobalt center dominates formulated product), pH-adjusted to ~5.5–7.0 for injection tolerance, and preserved with benzyl alcohol 0.9% in multi-dose vials. Because the mixture is compounded rather than manufactured under cGMP as a finished drug, potency assay, endotoxin testing, and beyond-use dating are controlled by the dispensing pharmacy rather than a shared specification. The marketing label 'lipotropic' — meaning 'fat-affinitive' — is inherited from 1930s nutritional biochemistry and describes a class of nutrients whose absence causes hepatic lipid accumulation; it does not mean 'causes fat loss.'

How it works

  1. 01

    Methionine — methyl donation via SAM and phosphatidylcholine synthesis

    Methionine is the precursor for S-adenosylmethionine (SAM), the universal methyl donor. In the liver, SAM provides methyl groups to the PEMT (phosphatidylethanolamine N-methyltransferase) pathway, which converts phosphatidylethanolamine to phosphatidylcholine — a required structural lipid for VLDL assembly and triglyceride export (Vance 2013, Biochim Biophys Acta). Methionine also feeds the transsulfuration pathway into cysteine and glutathione (Lu 2013, Mol Aspects Med). The mechanism is why dietary methionine-and-choline deficiency produces the MCD-diet model of NASH in rodents (Rinella 2008). The gap: methionine deficiency in well-fed humans is uncommon, and reversing a deficiency that does not exist is not a therapeutic mechanism. The methionine dose in a typical 1 mL Lipo-C injection (25 mg) is a small fraction of the ~2 g/day obtained from a normal Western diet.

  2. 02

    Inositol — PI/PIP signaling and insulin sensitization

    Myo-inositol is a precursor to phosphatidylinositol and its phosphorylated derivatives (PIP, PIP₂, PIP₃), which are central to insulin-receptor signal transduction via PI3K–Akt. Oral myo-inositol plus D-chiro-inositol at 2–4 g/day improves HOMA-IR and ovulation rate in polycystic ovary syndrome (Unfer 2017 systematic review and meta-analysis of 9 RCTs). That evidence is specifically oral, multi-gram, daily, in PCOS — and does not translate to a 50 mg intramuscular bolus once weekly in non-PCOS adults for weight loss. No IM or SC inositol dose-response study in humans has been published for any metabolic indication. Inositol's inclusion in MIC is mechanistically motivated, not clinically validated at the dose and route used.

  3. 03

    Choline — VLDL assembly via CDP-choline (Kennedy) pathway

    Choline is converted to phosphocholine by choline kinase, then to CDP-choline by CTP:phosphocholine cytidylyltransferase (the rate-limiting step), and finally combined with diacylglycerol to form phosphatidylcholine — the Kennedy pathway, which supplies most cellular PC (Gibellini 2010, IUBMB Life). Phosphatidylcholine is required for VLDL particle assembly; choline-deficient hepatocytes accumulate triglyceride because they cannot export it. Zeisel (2009, Annu Rev Nutr) established choline as an essential human nutrient with a recommended adequate intake of 425–550 mg/day. This is the strongest mechanistic arm of the Lipo-C story — but again, the clinical question is whether a 50 mg IM dose in a non-deficient adult drives net body-fat loss, and the answer from the published literature is that no trial has asked.

  4. 04

    Cyanocobalamin (B12) — the perceived-energy component

    B12 is a cofactor for methionine synthase (remethylating homocysteine to methionine) and L-methylmalonyl-CoA mutase. Deficiency causes megaloblastic anemia, peripheral neuropathy, and cognitive symptoms (Stabler 2013, N Engl J Med). IM injection is the definitive treatment for malabsorptive B12 deficiency (pernicious anemia) and raises serum B12 to supraphysiological levels within hours. In non-deficient adults, controlled trials of B12 supplementation for fatigue, cognition, and energy are negative or equivocal. The 'energy boost' commonly attributed to Lipo-C is most plausibly explained by the B12 component correcting unrecognized subclinical deficiency in a subset of patients — not by a lipotropic effect on body fat.

  5. 05

    Why the mechanism story does not justify the marketed claim

    Every component of Lipo-C has a coherent biochemistry — methionine feeds SAM, inositol feeds PI signaling, choline feeds VLDL assembly, B12 feeds methionine synthase. The clinical leap the marketing makes is from 'these molecules participate in lipid metabolism' to 'injecting them causes body-fat loss.' Every intermediate step — human deficiency baseline, dose-response at the clinical dose, route of administration vs the oral literature, net effect on body composition independent of concurrent caloric restriction — is unvalidated by controlled human data for the mixture as injected. That is why the grade is D and not C: the gap is not 'weak evidence,' it is the absence of any directly controlled evidence at all for the marketed indication.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Weight loss / fat loss (the dominant marketed indication)

    No RCT of MIC injection published; clinic chart reviews and testimonials only

  • Hepatic steatosis / NAFLD

    Oral choline for TPN-associated steatosis (Buchman 1995) is the closest controlled human signal; no MIC-injection trial

  • Energy / fatigue (attributed to B12)

    B12 injection is standard of care for frank deficiency; not for fatigue in replete adults

  • Insulin sensitivity / PCOS (attributed to inositol)

    Oral myo-inositol + D-chiro-inositol 2–4 g/day is B-graded in PCOS (Unfer 2017); not generalizable to IM MIC at 50 mg

  • Lipid profile improvement

    Oral choline/betaine (Olthof 2005) modest effects; no MIC-injection trial

  • Adjunct to GLP-1 therapy (semaglutide, tirzepatide)

    Clinic protocol only; no controlled isolation of the Lipo-C contribution

  • Postpartum / perimenopausal 'metabolic reset'

    Marketing indication; no published data

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    Whether the MIC combination as injected produces any weight-loss effect independent of caloric restriction. No placebo-controlled trial of MIC injection for weight loss has ever been published.

  • !

    Whether the dose of each component in a typical 1 mL IM injection (methionine ~25 mg, inositol ~50 mg, choline ~50 mg) is pharmacologically meaningful relative to dietary intake of the same molecules (~2 g methionine, ~500 mg choline, ~1 g total inositol per day from a normal Western diet).

  • !

    Whether there is any bioequivalence or route-equivalence case for IM MIC vs the oral component literature. The PCOS inositol RCTs, the TPN-choline trials, and the B12-deficiency studies all use oral or IV routes at very different doses.

  • !

    Sterility, endotoxin load, and potency variance across 503A compounders producing Lipo-C. FDA compounding risk alerts specifically flag injectable weight-loss compounds, and no multi-pharmacy quality survey has been published.

  • !

    Long-term (>12 month) safety of weekly IM B-complex + MIC injection in healthy-weight or mildly overweight adults. Published component-level safety does not address the chronic-exposure-in-non-deficient-adult scenario that matches the marketed use.

  • !

    Whether concomitant GLP-1 therapy (semaglutide, tirzepatide) interacts with the methylation-pathway load from injected methionine + B12 in any clinically meaningful way. No study has looked.

  • !

    Whether methionine restriction research (Orentreich 1993, Caro 2008 — long-lived-rodent methionine-restriction literature) implies that chronic supplementation is net harmful for longevity endpoints. The literature points in both directions and the question is unanswered in humans.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Lipo-Cand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • Lipotropic Injections for Weight Loss — What the Evidence Actually Shows

    Medlife Crisis·MD, Cardiology

    Walks through the absence of RCTs for MIC injection and the 1930s-rodent origin of the 'lipotropic' label. Explicit that the component-level oral literature does not transfer to the injected mixture at clinic doses.

    Verified credentials

  • MIC Injections and GLP-1s — Separating the Drug from the Add-on

    Peter Attia MD·MD, Internal Medicine / Longevity

    Makes the explicit case that observed weight loss in Lipo-C + semaglutide protocols is attributable to the GLP-1 based on STEP and SURMOUNT effect sizes, and that the MIC component adds expectancy and B12 correction but not isolated fat-loss signal.

    Verified credentials

  • I Got Lipo Shots for 30 Days — Honest Before & After

    Anonymous wellness influencer·Unverified

    Testimonial with concurrent calorie-deficit diet and no objective body-composition measurement. Representative of the marketing pattern FDA flagged in the 2023 consumer update. Do not weight against controlled evidence.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 18 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Formation and function of phosphatidylcholine and phosphatidylethanolamine in mammalian cells

    Vance DE · Biochim Biophys Acta · 2013

    Systematic reviewPMID 23140903
  2. [02]

    Glutathione synthesis

    Lu SC · Mol Aspects Med · 2013

    Systematic reviewPMID 23089296
  3. [03]

    The methionine-choline deficient dietary model of steatohepatitis

    Rinella ME, Green RM · J Hepatol · 2008

    AnimalPMID 18718904
  4. [04]

    Choline — an essential nutrient for public health

    Zeisel SH, da Costa KA · Nutr Rev · 2009

    Systematic reviewPMID 19694901
  5. [05]

    The Kennedy pathway — de novo synthesis of phosphatidylethanolamine and phosphatidylcholine

    Gibellini F, Smith TK · IUBMB Life · 2010

    Systematic reviewPMID 20364571
  6. [06]

    Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials

    Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J · Endocr Connect · 2017

    Meta-analysisPMID 28296078
  7. [07]

    Clinical practice: vitamin B12 deficiency

    Stabler SP · N Engl J Med · 2013

    Systematic reviewPMID 23301732
  8. [08]

    Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition — proof of a human choline requirement

    Buchman AL, Dubin MD, Moukarzel AA, et al. · Hepatology · 1995

    RCTPMID 7729214
  9. [09]

    Choline supplementation does not enhance the effects of betaine on plasma homocysteine, lipids, or liver function in healthy adults

    Olthof MR, Brink EJ, Katan MB, Verhoef P · Am J Clin Nutr · 2005

    RCTPMID 15930441
  10. [10]

    Choline and phosphatidylcholine — interpreting epidemiology and intervention studies

    Corbin KD, Zeisel SH · Curr Opin Gastroenterol · 2012

    Systematic reviewPMID 22249203
  11. [11]

    Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes

    Sherriff JL, O'Sullivan TA, Properzi C, Oddo JL, Adams LA · Adv Nutr · 2016

    Systematic reviewPMID 27807730
  12. [12]

    Low methionine ingestion by rats extends life span

    Orentreich N, Matias JR, DeFelice A, Zimmerman JA · J Nutr · 1993

    AnimalPMID 8419524
  13. [13]

    Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

    Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med · 2021

    RCTPMID 34019122
  14. [14]

    Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. · N Engl J Med · 2022

    RCTPMID 35658024
  15. [15]

    FDA consumer update — compounded versions of unapproved weight-loss drugs, with guidance reiterated through 2025 compounding risk alerts

    U.S. Food and Drug Administration, Office of Compounding Quality and Compliance · FDA · 2023

    RegulatoryLink
  16. [16]

    FDA 503A Bulk Drug Substances Categories — April 15, 2026 Update (compounded injectable weight-loss products flagged for compliance attention)

    U.S. Food and Drug Administration · FDA · 2026

    RegulatoryLink
  17. [17]

    FDA approval history for cyanocobalamin injection (NDA 080250) — approved for vitamin B12 deficiency, not weight loss

    U.S. Food and Drug Administration · FDA Orange Book · 1982

    RegistrationLink
  18. [18]

    WADA 2026 Prohibited List (in force January 1, 2026) — MIC components not named; S0 non-approved-substances clause may apply to compounded preparations

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink

§ Adjacent peptides

Worth reading
alongside this.

Compare

Glutathione

Adjacent clinic-compounded injectable marketed with a mechanism-forward, evidence-thin story. Same 503A-compounding regulatory pattern, same gap between component-level biochemistry and the injected-mixture claim.

Read its grades

Compare

Vitamin B12 (cyanocobalamin / methylcobalamin)

The B12 component is the most-often-cited 'active' ingredient in Lipo-C. The evidence-grade story for injectable B12 — A for frank deficiency, D for fatigue in replete adults — is the single most important sub-page for understanding what Lipo-C actually does for most patients.

Read its grades

Compare

NAD+ (IV / IM infusion)

Another wellness-clinic injectable priced on a weekly-cadence model with a mechanism-forward story and thin controlled-efficacy evidence for the marketed indications. Shares the '503A compounded, no RCT for the marketed claim, confounded by concurrent interventions' evidence pattern.

Read its grades

Compare

AOD-9604

Another 'fat-loss' compound marketed by weight-loss clinics with a component-level mechanism narrative that runs ahead of controlled human data. The AOD-9604 Phase 2 trials are the cleanest example of what a real fat-loss RCT looks like — and of how Lipo-C has never had one.

Read its grades

Where to research further

Looking for Lipo-C
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →